On Jun. 5, 2020, BioSig Technologies and its subsidiary, ViralClear Pharma, announced it had expanded its patient enrollment centers to include St. Davidﾒs South Austin Medical Center in Austin. The hospital is part of St. Davidﾒs HealthCare, one of the largest healthcare systems in Texas. The Company intends to commence its Phase II clinical trial for merimepodib, its broad-spectrum oral anti-viral candidate for the treatment of COVID-19 in adult patients in the coming months.